| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/08/2001 | CA2387507A1 Communications system |
| 03/08/2001 | CA2384435A1 Bicyclic androgen and progesterone receptor modulator compounds and methods |
| 03/08/2001 | CA2384194A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of inflammation |
| 03/08/2001 | CA2384126A1 Reverse-turn mimetics and methods relating thereto |
| 03/08/2001 | CA2384026A1 Dna encoding a human subunit 5-ht3-c of the 5-ht3 serotonin receptor |
| 03/08/2001 | CA2383877A1 Method for detecting the expression of an envelope protein of a human endogenous retrovirus and uses of a gene coding for said protein |
| 03/08/2001 | CA2383783A1 Use of bis-sulfonamides for producing medicaments used for preventing or treating hyperlipidaemia |
| 03/08/2001 | CA2383781A1 Sulfonyl carboxamide derivatives, method for their production and their use as medicaments |
| 03/08/2001 | CA2383693A1 Card proteins involved in cell death regulation |
| 03/08/2001 | CA2383519A1 Antibody dependent enhancement (ade) of alphavirus infection |
| 03/08/2001 | CA2383347A1 Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes |
| 03/08/2001 | CA2383329A1 4,5-diaryloxazole compounds with prostaglandin 12 (pg12) agonistic activity |
| 03/08/2001 | CA2383077A1 Androgen receptor modulator compounds and methods |
| 03/08/2001 | CA2383002A1 Substituted .alpha.-hydroxy acid caspase inhibitors and the use thereof |
| 03/08/2001 | CA2382966A1 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 03/08/2001 | CA2382953A1 Dna encoding the human serine protease c-e |
| 03/08/2001 | CA2382835A1 Use of amino acids for making medicines for treating to insulin-resistance |
| 03/08/2001 | CA2382789A1 Phosphate mimics and methods of treatment using phosphatase inhibitors |
| 03/08/2001 | CA2382611A1 Compositions for stimulating cytokine secretion and inducing an immune response |
| 03/08/2001 | CA2382567A1 Use of at least one substance based on nicotine and/or a substance produced from said one substance for the manufacture of a medicament, and a method for treatment of obstructive lung disease |
| 03/08/2001 | CA2382562A1 Compositions and methods for modulating hdl cholesterol and triglyceride levels |
| 03/08/2001 | CA2382556A1 Coformulation methods and their products |
| 03/08/2001 | CA2382551A1 Plant extract mixtures and their uses |
| 03/08/2001 | CA2382529A1 Treatment of pancreatic disease |
| 03/08/2001 | CA2382499A1 Method for coupling molecules |
| 03/08/2001 | CA2382449A1 Metal-containing compositions, preparations and uses |
| 03/08/2001 | CA2382427A1 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 03/08/2001 | CA2382345A1 Extended duration light activated cancer therapy |
| 03/08/2001 | CA2382259A1 Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
| 03/08/2001 | CA2382100A1 Dosages for treatment with anti-erbb2 antibodies |
| 03/08/2001 | CA2382034A1 Medicaments that contain xenogenic oligo- or/and polyribonucleotides |
| 03/08/2001 | CA2382030A1 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 03/08/2001 | CA2381926A1 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| 03/08/2001 | CA2381924A1 Color safe laundry methods employing zwitterionic formulation components |
| 03/08/2001 | CA2381895A1 Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome |
| 03/08/2001 | CA2381849A1 Antimycotic drug |
| 03/08/2001 | CA2381821A1 Substituted indolinones, their manufacture and their use as medicaments |
| 03/08/2001 | CA2381813A1 Treatment of fungal infections utilizing a fungal growth medium |
| 03/08/2001 | CA2381553A1 Fused pyrrolecarboxamides: gaba brain receptor ligands |
| 03/08/2001 | CA2381451A1 Attractin-like polynucleotides, polypeptides, and antibodies |
| 03/08/2001 | CA2381239A1 Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes |
| 03/08/2001 | CA2379421A1 Sulfonylphenylpyrazole compounds useful as cox-2 inhibitors |
| 03/08/2001 | CA2378298A1 8-substituted-6-trifluoromethyl-9-pyrido¬3,2-g|quinoline compounds as androgen receptor modulators |
| 03/08/2001 | CA2348565A1 Methods and compositions for selective cancer chemotherapy |
| 03/07/2001 | EP1081172A1 Sulfonated comb polymers and preparations with selected Lithium/Sodium-ratio, especially hair cosmetic preparations based on such sulfonated comb polymers |
| 03/07/2001 | EP1081155A2 N6 heterocyclic substituted adenosine derivatives |
| 03/07/2001 | EP1081151A1 Novel physiologically active substances |
| 03/07/2001 | EP1081148A2 Enantiomerically pure beta-D-dioxolane-nucleosides |
| 03/07/2001 | EP1081146A1 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 03/07/2001 | EP1081144A2 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 03/07/2001 | EP1081143A1 Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
| 03/07/2001 | EP1081142A2 Novel N-Aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
| 03/07/2001 | EP1081138A1 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds |
| 03/07/2001 | EP1081137A1 Selective inhibitors of aggrecanase in osteoarthritis treatment |
| 03/07/2001 | EP1081135A2 1H-indole-3-glyoxylamide spla2 inhibitors |
| 03/07/2001 | EP1081131A1 Selective anti-mycobacterial preparations, method for producing the same and pharmaceutical compositions |
| 03/07/2001 | EP1080733A1 Solid preparations for oral administration of drugs relating to genes |
| 03/07/2001 | EP1080730A1 Minoxidil compositions for external use |
| 03/07/2001 | EP1080729A1 Cervical ripening agent and cervical ripening method |
| 03/07/2001 | EP1080728A1 Prostaglandin ep4 receptor agonist and treatment method |
| 03/07/2001 | EP1080726A1 Agents for relieving side effects |
| 03/07/2001 | EP1080725A1 Use of fluoroquinolones for treating atherosclerosis |
| 03/07/2001 | EP1080724A1 Mtp activity-lowering compositions |
| 03/07/2001 | EP1080723A1 INHIBITION OF IgA PRODUCTION |
| 03/07/2001 | EP1080722A1 Antimycotic compositions |
| 03/07/2001 | EP1080721A2 Non-crystalline solid dispersant comprising cefuromixe axetil |
| 03/07/2001 | EP1080720A1 Fat emulsions for inhalational administration |
| 03/07/2001 | EP1080717A1 Method for dispensing antioxidant vitamins by inhalation |
| 03/07/2001 | EP1080716A1 Annelated benzene derivatives as antioxidants and radical scavengers in cosmetic preparations |
| 03/07/2001 | EP1080233A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products |
| 03/07/2001 | EP1080226A1 Compositions and methods for topical delivery of oligonucleotides |
| 03/07/2001 | EP1080225A1 Compositions and methods for the pulmonary delivery of nucleic acids |
| 03/07/2001 | EP1080202A2 Convection-enhanced delivery of aav vectors |
| 03/07/2001 | EP1080199A2 (hemorrhagic enteritis) virus dna sequences, proteins encoded thereby and various uses thereof |
| 03/07/2001 | EP1080195A1 Endometriosis-associated gene |
| 03/07/2001 | EP1080192A2 Antisense oligonucleotides for treating proliferating cells |
| 03/07/2001 | EP1080189A1 Compositions and methods for the synthesis of fatty acids, their derivatives and downstream products |
| 03/07/2001 | EP1080184A1 Method for activating natural killer (nk) cells |
| 03/07/2001 | EP1080181A1 clpX OF STREPTOCOCCUS PNEUMONIAE |
| 03/07/2001 | EP1080110A2 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| 03/07/2001 | EP1080105A1 Phenylalanine derivatives having vla-4 antagonistic activity |
| 03/07/2001 | EP1080103A1 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 03/07/2001 | EP1080100A1 Cytosine deaminase gene |
| 03/07/2001 | EP1080095A1 Modulators of protein tyrosine phosphatases (ptpases) |
| 03/07/2001 | EP1080094A1 G-csf mimetics |
| 03/07/2001 | EP1080093A1 G-csf mimetics |
| 03/07/2001 | EP1080092A2 Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| 03/07/2001 | EP1080091A1 Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| 03/07/2001 | EP1080090A1 Antitumour 1,5-diazaanthraquinones |
| 03/07/2001 | EP1080087A1 Novel 2-alkyl substituted imidazole compounds |
| 03/07/2001 | EP1080086A1 Dihydropyrimidines |
| 03/07/2001 | EP1080083A1 Novel heterocyclically substituted amides with cysteine protease-inhibiting effect |
| 03/07/2001 | EP1080081A1 Benzofuroxan derivatives and their use in treating angina pectoris |
| 03/07/2001 | EP1080080A1 Novel therapeutic agents that modulate neurokinin receptors |
| 03/07/2001 | EP1080079A1 Thermally stable trimetrexates and processes for producing the same |
| 03/07/2001 | EP1080078A1 Heterocyclic compounds and methods to treat cardiac failure and other disorders |
| 03/07/2001 | EP1080075A1 Piperididinyl and n-amidinopiperidinyl derivatives |
| 03/07/2001 | EP1080074A1 New heterocyclically substituted amides, their production and their use |
| 03/07/2001 | EP1080073A1 Compositions comprising 2-phenyl-indole compounds and estrogen formulations |
| 03/07/2001 | EP1080070A2 Antiangiogenic drug to treat cancer, arthritis and retinopathy |